MichaelaLiedtkeMD

Hematology • Stanford, CA

Assistant Professor, Medicine - Hematology, Stanford University Medical Center

Join to view full profile

Dr. Liedtke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liedtke's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2004 - 2006
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2004
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1998 - 2002
Hannover Medical SchoolClass of 1996

Certifications & Licensure

CA State Medical License 2004 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM Start of enrollment: 2010 Aug 01
Completed
Phase 1
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2013 May 01
Completed
Phase 2
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2013 Mar 01
Completed
Phase 2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Start of enrollment: 2014 Jun 13
Completed
Phase 1
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Start of enrollment: 2019 Sep 23
Active, not recruiting
Phase 1
Roles: Contact
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab Start of enrollment: 2021 Apr 14
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2020 Nov 30
Completed
Phase 1, Phase 2
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Start of enrollment: 2024 Feb 15
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

22 citations
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Robert F. Cornell, Parameswaran Hari, Shijie Tang, Noa Biran, Natalie S. Callander
American Journal of Hematology. 2021-01-01
1001 citations
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje, Jesus G. Berdeja, Yi Lin, David S. Siegel, Sundar Jagannath
The New England Journal of Medicine. 2019-05-01
850 citations
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Giovanni Martinelli, Michaela Liedtke
The New England Journal of Medicine. 2016-06-12

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Michaela Liedtke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
Michaela Liedtke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemi...
Michaela Liedtke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses
Michaela Liedtke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis
Michaela Liedtke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Michaela Liedtke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 12/3/2018
A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphocytic Leukemia
60th American Society of Hematology Annual Meeting - 12/1/2018

Authored Content

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network TrialDecember 2022

Press Mentions

$Venetoclax Induces Deep Hematologic Remissions in T(11;14) relapsed/refractory AL Amyloidosis$
Venetoclax Induces Deep Hematologic Remissions in T(11;14) relapsed/refractory AL AmyloidosisJanuary 11th, 2021
Another Milestone in the JACC Family of Journals: First Issue of JACC: CardioOncology ReleasedOctober 18th, 2019
Immunotherapies in ALL: What’s Best and What’s Next?March 6th, 2019
Join now to see all